<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03905707</url>
  </required_header>
  <id_info>
    <org_study_id>ZP1848-17127</org_study_id>
    <nct_id>NCT03905707</nct_id>
  </id_info>
  <brief_title>Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS</brief_title>
  <acronym>EASE SBS 2</acronym>
  <official_title>A Double-Blind Phase 3 Extension Trial Assessing the Long Term Safety and Efficacy of Glepaglutide in Patients With Short Bowel Syndrome (SBS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zealand Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zealand Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the trial is to evaluate the long-term safety of glepaglutide
      treatment in patients with short bowel syndrome (SBS).

      Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Double-Blind Phase 3 Extension Trial Assessing the Long Term Safety and Efficacy of
      Glepaglutide in Patients with Short Bowel Syndrome (SBS)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2019</start_date>
  <completion_date type="Anticipated">November 5, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 5, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety - Adverse Events</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence and type of Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety - Serious Adverse Events</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence and type of Serious Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Adverse Events of Special Interest</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence and type of Adverse Events of Special Interest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Changes in blood pressure from baseline</measure>
    <time_frame>2 years</time_frame>
    <description>Changes in systolic and diastolic blood pressure will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant changes in 12-Lead electrocardiogram (ECG)</measure>
    <time_frame>2 years</time_frame>
    <description>Number of patients with clinically significant changes in ECG will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity - Occurrence of anti-drug antibodies</measure>
    <time_frame>2 years</time_frame>
    <description>Occurrence of antibodies against glepaglutide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weekly Parenteral Support (PS) volume</measure>
    <time_frame>2 years</time_frame>
    <description>Change in weekly PS volume from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with 20 percent reduction in PS volume</measure>
    <time_frame>2 years</time_frame>
    <description>Achieving at least 20 percent reduction in weekly PS volume from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days off PS</measure>
    <time_frame>2 years</time_frame>
    <description>Achieving 1 or more days per week off PS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weaned off PS</measure>
    <time_frame>2 years</time_frame>
    <description>Reduction in weekly PS volume of 100 percent (weaned off)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fluid composite effect</measure>
    <time_frame>2 years</time_frame>
    <description>Reduction in PS plus reduction in oral fluid intake plus increase in urine volume from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Energy content (lipids)</measure>
    <time_frame>2 years</time_frame>
    <description>Change in lipids content (in kcal/L or kjoule/L) of PS from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Energy content (glucose)</measure>
    <time_frame>2 years</time_frame>
    <description>Change in glucose content (in kcal/L or kjoule/L) of PS from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Energy content (amino acids)</measure>
    <time_frame>2 years</time_frame>
    <description>Change in amino acids content (in kcal/L or kjoule/L) of PS from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days on PS</measure>
    <time_frame>2 years</time_frame>
    <description>Change in number of days on PS per week from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with 40 percent change in PS volume per week</measure>
    <time_frame>2 years</time_frame>
    <description>Achieving 40 percent in PS volume from baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">145</enrollment>
  <condition>Short Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Glepaglutide SC injections twice weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glucagon-Like Peptide-2 (GLP-2) analog, 10 mg subcutaneous injection twice weekly.
In this long term safety study, there is no placebo arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glepaglutide SC injections once weekly and placebo once weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glucagon-Like Peptide-2 (GLP-2) analog, 10 mg subcutaneous injection once weekly and placebo once weekly.
In this long term safety study, there is no placebo arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glepaglutide</intervention_name>
    <description>Glucagon-Like Peptide-2 (GLP-2) analog</description>
    <arm_group_label>Glepaglutide SC injections once weekly and placebo once weekly</arm_group_label>
    <arm_group_label>Glepaglutide SC injections twice weekly</arm_group_label>
    <other_name>ZP1848</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent obtained before any trial-related activity

          -  Completed the lead-in trial (ZP1848-17111) or completed the Phase 2 trial
             (ZP1848-15073)

        Exclusion Criteria:

          -  Withdrawal of consent from the lead-in trial

          -  Any condition or disease or circumstance that in the Investigator's opinion would put
             the patient at any undue risk, prevent completion of the trial, or interfere with the
             analysis of the trial results

          -  Use of GLP-1, GLP-2, human growth hormone, somatostatin, or analogs thereof, within 3
             months prior to Screening

          -  Females of childbearing potential, who are pregnant, breast-feeding, intend to become
             pregnant or are not using highly effective contraceptive methods
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zealand Pharma</last_name>
    <role>Study Director</role>
    <affiliation>Zealand Pharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Associate Medical Director</last_name>
    <phone>+4588773600</phone>
    <email>mag@zealandpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clinical Trial Manager</last_name>
    <phone>+4588773600</phone>
    <email>teg@zealandpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miami Transplant Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Division of Gastroenterology and Hepatology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago Children's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic College of Medicine</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-3285</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center, Nashville</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>68198-3285</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Erasme</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Royal Alexandra Hospital</name>
      <address>
        <city>Edmonton</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Health Network - Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de l'Archet</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon-Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt - Med. Klinik I</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Rostock</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen - Innere Medizin I</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Federico II</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMC Radboud Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Solumed</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Skawina sp. z o.o. im. Stanley Dudricka</name>
      <address>
        <city>Skawina</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Specjalistyczny Szpital im. M. Pirogowa w Lodzi</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Mark's Hospital</name>
      <address>
        <city>Harrow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLH Foundation NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Salford Royal NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of East Anglia</name>
      <address>
        <city>Norwich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton NHS Foundation Trust</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>March 28, 2019</study_first_submitted>
  <study_first_submitted_qc>April 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2019</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Short Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

